The price-to-earnings ratio for Quest Diagnostics, Inc. (NYSE: DGX) is above average at 19.16x. The 36-month beta value for DGX is also noteworthy at 0.88. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 14 rating it as “hold,” and 1 rating it as “sell.”
The public float for DGX is 110.55M, and at present, short sellers hold a 2.05% of that float. The average trading volume of DGX on July 23, 2024 was 906.72K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
DGX) stock’s latest price update
Quest Diagnostics, Inc. (NYSE: DGX) has experienced a decline in its stock price by -3.36 compared to its previous closing price of 147.35. However, the company has seen a fall of -4.17% in its stock price over the last five trading days. zacks.com reported 2024-07-23 that Quest Diagnostics (DGX) delivers impressive base business growth in the second quarter of 2024.
DGX’s Market Performance
Quest Diagnostics, Inc. (DGX) has seen a -4.17% fall in stock performance for the week, with a 2.48% gain in the past month and a 9.47% surge in the past quarter. The volatility ratio for the week is 2.09%, and the volatility levels for the past 30 days are at 1.83% for DGX. The simple moving average for the past 20 days is 0.51% for DGX’s stock, with a 6.57% simple moving average for the past 200 days.
Analysts’ Opinion of DGX
Many brokerage firms have already submitted their reports for DGX stocks, with Citigroup repeating the rating for DGX by listing it as a “Buy.” The predicted price for DGX in the upcoming period, according to Citigroup is $165 based on the research report published on July 10, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see DGX reach a price target of $135. The rating they have provided for DGX stocks is “Market Perform” according to the report published on February 26th, 2024.
Jefferies gave a rating of “Buy” to DGX, setting the target price at $155 in the report published on February 07th of the current year.
DGX Trading at 1.05% from the 50-Day Moving Average
After a stumble in the market that brought DGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.43% of loss for the given period.
Volatility was left at 1.83%, however, over the last 30 days, the volatility rate increased by 2.09%, as shares sank -1.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.27% upper at present.
During the last 5 trading sessions, DGX fell by -6.78%, which changed the moving average for the period of 200-days by +13.01% in comparison to the 20-day moving average, which settled at $141.60. In addition, Quest Diagnostics, Inc. saw 3.28% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DGX starting from KUPPUSAMY KARTHIK, who sale 1,760 shares at the price of $140.00 back on Apr 29 ’24. After this action, KUPPUSAMY KARTHIK now owns 13,435 shares of Quest Diagnostics, Inc., valued at $246,400 using the latest closing price.
PREVOZNIK MICHAEL E, the SVP & General Counsel of Quest Diagnostics, Inc., sale 5,611 shares at $125.88 during a trade that took place back on Feb 29 ’24, which means that PREVOZNIK MICHAEL E is holding 38,478 shares at $706,313 based on the most recent closing price.
Stock Fundamentals for DGX
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.33 for the gross margin
The net margin for Quest Diagnostics, Inc. stands at 0.09. The total capital return value is set at 0.11. Equity return is now at value 13.49, with 6.30 for asset returns.
Based on Quest Diagnostics, Inc. (DGX), the company’s capital structure generated 0.43 points at debt to capital in total, while cash flow to debt ratio is standing at 0.27. The debt to equity ratio resting at 0.76. The interest coverage ratio of the stock is 7.95.
Currently, EBITDA for the company is 1.79 billion with net debt to EBITDA at 2.75. When we switch over and look at the enterprise to sales, we see a ratio of 2.21. The receivables turnover for the company is 7.02for trailing twelve months and the total asset turnover is 0.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.97.
Conclusion
In summary, Quest Diagnostics, Inc. (DGX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
